Home › Kidney Cancer (Renal Cell Carcinoma) › New York
Kidney Cancer (Renal Cell Carcinoma) clinical trials in New York
36 studies for Kidney Cancer (Renal Cell Carcinoma) are looking for participants at sites in New York.
Cities in New York
- New York City27 studies
- Queens15 studies
- Greenburgh8 studies
- Staten Island7 studies
- New Rochelle7 studies
- Buffalo6 studies
- Rochester3 studies
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
- Research Site, New York
- Research Site, New York
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 5, 2026 · NCT05536141Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
- NEO-811 Long Island Site, Lake Success
- NEO-811 NYC Site, New York
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 5, 2026 · NCT07300241A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
- START New York Long Island LLC, Lake Success
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT06270706A Phase 1 Study of the Safety and Tolerability of CTX-10726
- START New York, Lake Success
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT07419841Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)
- Perlmutter Cancer Center at NYU Langone Hospital - Long Island ( Site 5026), Mineola
- Laura and Isaac Perlmutter Cancer Center ( Site 5016), New York
- Memorial Sloan Kettering Cancer Center ( Site 5002), New York
RecruitingPhase 1/2
Ages 18 to 120 · All sexes · Updated Oct 2, 2026 · NCT07049926A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma
- Memorial Sloan Kettering Cancer Center, New York
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 2, 2026 · NCT06234605Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Queens Hospital Center, Jamaica
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
- Stony Brook University Medical Center, Stony Brook
RecruitingObservational studyHealthy volunteers welcome
Ages 40 to 75 · All sexes · Updated Oct 2, 2026 · NCT05334069Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Exelixis Clinical Site #60, New York
- Exelixis Clinical Site #6, New York
- Exelixis Clinical Site #76, Syracuse
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT05176483Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma
- Roswell Park Comprehensive, Buffalo
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT05287945Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
- Memorial Sloan Kettering Commack, Commack
- Memorial Sloan Kettering Westchester, Harrison
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
- and 3 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT03866382Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
- NYU Langone Medical Center, New York
RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT04981119A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)
- Memorial Sloan Kettering Cancer Center ( Site 0126), New York
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07489495A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
- Memorial Sloan Kettering Cancer Center, New York
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT07293351Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC
- Columbia University Irving Medical Center, New York
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT06863311Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
- Northwell Health Imbert Cancer Center, Bay Shore
- Memorial Sloan Kettering Commack, Commack
- Glens Falls Hospital, Glens Falls
- and 10 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 18, 2026 · NCT05327686Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
- New York Oncology Hematology, P.C., Albany
- New York Oncology Hematology - Clifton Park Cancer Center, Clifton Park
- MSK Commack, Commack
- and 7 more
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 17, 2026 · NCT07227415A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
- Memorial Sloan Kettering Cancer Center, New York
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 15, 2026 · NCT07195916GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors
- Tisch Cancer Institute (TCI), Icahn School of Medicine, New York
- Columbia University, New York
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT04977453Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
- Roswell Park Cancer Institute, Buffalo
- Hematology Oncology Associates of CNY at Camillus, Camillus
- Memorial Sloan Kettering Commack, Commack
- and 13 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 2, 2026 · NCT06661720A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
- Memorial Sloan Kettering Suffolk- Commack (Limited Protocol Activities), Commack
- Memorial Sloan Kettering Westchester (All Protocol Activities), Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
- and 1 more
Recruiting
Ages 18 and older · All sexes · Updated Sep 2, 2026 · NCT05837767Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
- New York Cancer & Blood Specialists, New York
- University of Rochester - Wilmot Cancer Institute, Rochester
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 27, 2026 · NCT06582017Comparing Two Weight Loss Programs for the Prevention of Kidney Cancer Progression Among Patients With Small Renal Masses on Active Surveillance
- Roswell Park Comprehensive Cancer Center, Buffalo
Recruiting
Ages 18 and older · All sexes · Updated Aug 20, 2026 · NCT07714018A Study of MGC026 in Participants With Advanced Solid Tumors
- START-New York Long Island, Lake Success
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 11, 2026 · NCT06242470A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
- Memorial Sloan Kettering Cancer Center, New York
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 11, 2026 · NCT07195682Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
- Xencor Investigative Site, New York
- Xencor Investigative Site, New York
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 3, 2026 · NCT05433142A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
- NYU Langone Health Perlmutter Cancer Center, New York
- Icahn School of Medicine at Mount Sinai, New York
- Columbia University - The Trustees of Columbia University in the City of New York, New York
- and 2 more
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jul 9, 2026 · NCT03972657A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC)
- Memorial Sloan Kettering Cancer Center Suffolk - Commack (Limited Protocol Activities), Commack
- Memorial Sloan Kettering West Harrison (Limited Protocol Activities), Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activites), New York
- and 1 more
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jun 24, 2026 · NCT06835972Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
- NYU Laura and Isaac Perlmutter Cancer Center - 34th Street /ID# 257869, New York
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 4, 2026 · NCT04777994A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body
- Northwell Health, Lake Success
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Apr 28, 2026 · NCT06413680Study to Evaluate the Safety and Efficacy of Bicalutamide in Combination With Sunitinib in Patients With TKIs-resistant RCC
- UB/ Great Lakes Cancer Care, Buffalo
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Apr 1, 2026 · NCT06222593A Study of Cemiplimab and Fianlimab in People With Clear Cell Renal Cell Carcinoma
- Memorial Sloan Kettering Cancer Center Suffolk - Commack (Limited Protocol Activities), Commack
- Memorial Sloan Kettering West Harrison (Limited Protocol Activities), Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activites), New York
- and 1 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Mar 4, 2026 · NCT06699602Decision Aid (DA) for Renal Patients
- NYU Langone Health, New York
Recruiting
Ages 18 and older · All sexes · Updated Dec 2, 2025 · NCT05387863A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
- NYU Langone Health, New York
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 9, 2025 · NCT06682793Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial
- Roswell Park Cancer Institute, Buffalo
- Northwell Health/Center for Advanced Medicine, Lake Success
- University of Rochester, Rochester
- and 1 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 9, 2025 · NCT04510597A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
- Memorial Sloan-Kettering Cancer Center, New York
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 25, 2024 · NCT05824975Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
- Roswell Park Cancer Institute, Buffalo
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 15, 2024 · NCT04787042From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.